Analysis of the structure of comorbidities and pharmacotherapy in patients with a combination of atrial fibrillation and coronary heart disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Atrial fibrillation (AF) and coronary heart disease (CHD) mutually worsen the course and prognosis of each other, especially in the presence of a history of previous myocardial infarction. Such a combination of diseases is more common in elderly and senile patients, which requires special control of pharmacotherapy due to the high prevalence of polypharmacia.

Objective. Analysis of the structure of comorbidities and compliance of prescribed pharmacotherapy with STOPP/START criteria in hospitalized patients ≥65 years old with a combination of AF and CHD, depending on the presence of previous myocardial infarction. Methods. We conducted a retrospective analysis of the medical histories of 342 patients ≥65 years old with a combination of AF and CHD who were treated in the cardiology department of a multidisciplinary hospital in Moscow, and divided them into groups: group 1 – 214 patients, median age 85 (78–90) years without history of previous myocardial infarction and a group 2 – 128 patients, median age 85.5 (78–90) years with a history of previous myocardial infarction. The comparative analysis of the structure of multimorbidity and pharmacotherapy according to STOP/START criteria was carried out.

RESULTS. In the second group, the score on the CHA2DS2-VASc (p<0.001), the value of the Charlson comorbidity index (p<0.001), and the number of maximally prescribed drugs at the same time (p=0.002) were significantly higher. Among the comorbidities in patients with a history of previous myocardial infarction, there were chronic heart failure of functional class IV according to the New York Heart Association (NYHA) classification (p=0.006), type 2 diabetes mellitus (p=0.005), stage 3b chronic kidney disease (p=0.019) more common. START criteria were more common than STOPP criteria, and we also found two START criteria with significant differences in frequency between groups.

Conclusions. The data obtained requires more careful selection of medicines in elderly patients. STOPP/START criteria can be recommended to use to select the optimal treatment strategy.

Full Text

Restricted Access

About the authors

A. V. Dubinina

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0009-0008-6383-0016
Russian Federation, Moscow

Alexey I. Kochetkov

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: ak_info@list.ru
ORCID iD: 0000-0001-5801-3742

Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology n.a. Academician M.S. Vovsin

Russian Federation, Moscow

А. E. Vorobieva

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0000-0003-1183-4716
Russian Federation, Moscow

S. S. Eremina

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0000-0001-7989-354X
Russian Federation, Moscow

K. B. Mirzaev

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0000-0002-9307-4994
Russian Federation, Moscow

O. D. Ostroumova

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0000-0002-0795-8225
Russian Federation, Moscow

References

  1. Schnabel R.B., Yin X., Gona P., et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154–62. doi: 10.1016/S01406736(14)61774-8.
  2. Hindricks G., Potpara T., Dagres N., et al. Рекомендации ESC 2020 по диагностике и лечению пациентов с фибрилляцией предсердий, разработанные совместно с европейской ассоциацией кардиоторакальной хирургии (EACTS). Российский кардиологический журнал. 2021;26(9):4701. [Hindricks G., Potpara T., Dagres N., et al. ESC 2020 guidelines for the diagnosis and treatment of patients with atrial fibrillation, developed jointly with the European Association of Cardiothoracic Surgery (EACTS). Russ J Cardiol. 2021;26(9):4701. (In Russ.)]. doi: 10.15829/1560-4071-2021-4701.
  3. Мареев Ю.В., Поляков Д.С., Виноградова Н.Г., и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации. Кардиология. 2022;62(4):12–9. [Mareev Yu.V., Polyakov D.S., Vinogradova N.G., et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Cardiologiya. 2022;62(4):12–9. (In Russ.)].
  4. Colilla S., Crow A., Petkun W., et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am J Cardiol. 2013;112(8):1142–47. doi: 10.1016/j.amjcard.2013.05.063 9.
  5. Heeringa J., van der Kuip D.A.M., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53. doi: 10.1093/eurheartj/ehi825.
  6. GBD 2017 Causes of Death Collaborators. Global, regional and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). 2018;392(10159):1736–88. doi: 10.1016/S0140-6736(18)32203-7.
  7. O’Neal W.T., Soliman E.Z., Howard G., et al. Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic and Racial Differences in Stroke study. Atherosclerosis. 2015;243(1):192–97. doi: 10.1016/j.atherosclerosis.2015.09.009.
  8. Клинические рекомендации «Фибрилляция и трепетание предсердий у взрослых». Год утверждения: 2020. [Internet] [cited 2023 Nov 18]. [Clinical recommendations “Atrial fibrillation and flutter in adults”. Year of approval: 2020. [Internet] [city 2023, Nov 18] (In Russ.)]. URL: https://cr.minzdrav.gov.ru/ recomend/382_1.
  9. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77. doi: 10.1093/eurheartj/ehx393.
  10. Lip G.Y.H., Tran G., Genaidy A., et al. Prevalence/incidence of atrial fibrillation based on integrated medical/pharmacy claims, and association with co-morbidity profiles/multi-morbidity in a large US adult cohort. Int J Clin Pract. 2021;75:e14042.
  11. Kotalczyk A., Guo Y., Wang Y., Lip G.Y.H. On behalf of the chi ori. impact of multimorbidity and polypharmacy on clinical outcomes of elderly Chinese patients with atrial fibrillation. J Clin Med. 2022;11:1370.
  12. Cычев Д.А. Полипрагмазия в клинической практике: проблема и решения. 2-издание. СПб., 2018. 272 с. [Sychev D.A. Polypharmacy in clinical practice: a problem and solutions. 2nd edition. SPb., 2018. 272 p. (In Russ.)].
  13. Cruz-Jentoft A.J., Boland B., Rexach L. Drug therapy optimization at the end of life. Drugs Aging. 2012;29(6):511–21. doi: 10.2165/11631740-000000000-00000.
  14. Konrat C., Boutron I., Trinquart L., et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One. 2012;7(3):e33559. doi: 10.1371/journal.pone.0033559.
  15. Beers M.H., Ouslander J.G., Rollingher I., et al. Explicit criteria for determi ninginappropri ate medication use in nursing home residents. Arch Intern Med. 1991;151(9):1825–32. doi: 10.1001/archinte.1991.00400090107019.
  16. O’Mahony D., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;,4:625–32. doi: 10.1007/s41999-023-00777-y.
  17. Gallagher P., Ryan C., Byrne S., et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83. doi: 10.5414/CPP46072.
  18. Методическое руководство «Фармакотерапия у лиц пожилого и старческого возраста» Министерства Здравоохранения Российской Федерации. Год утверждения: 2018. [Internet] [cited 2023 Nov 18]. [Methodological guide «Pharmacotherapy in elderly and senile persons» of the Ministry of Health of the Russian Federation. Year of approval: 2018. [Internet] [city 2023, Nov 18 (In Russ.)]. URL: https://apicr.minzdrav.gov.ru/Files/recomend/%D0%9C%D0%A0103.PDF
  19. Общие принципы фармакотерапии у лиц пожилого и старческого возраста: Методические рекомендации. Под ред. О.Н. Ткачевой. М., 2019. 66 с. [General principles of pharmacotherapy in elderly and senile people: Methodological recommendations. Ed. by O.N. Tkacheva. M., 2019. 66 p. (In Russ.)].
  20. O’Mahony D., O’Sullivan D., Byrne S., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–18. doi: 10.1093/ageing/afu145.
  21. Andersson T., Magnuson A., Bryngelsson I.L., et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur. Heart J. 2013;34:1061–67. doi: 10.1093/eurheartj/ehs469.
  22. Vanbeselaere V., Truyers C., Elli S., et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC. Cardiovasc Disord. 2016;16:61. doi: 10.1186/s12872-016-0235-1.
  23. LaMori J.C., Mody S.H., Gross H.J., et al. Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013;7:53–62. doi: 10.1177/1753944712464101.
  24. Guo X., Li M., Du X., et al. Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study. Front Cardiovasc Med. 2022;9:988799. doi: 10.3389/fcvm.2022.988799.
  25. Balakrishnan S., Karmacharya I., Ghimire S., et al. Prevalence of multimorbidity and its correlates among older adults in Eastern Nepal. BMC. Geriatr. 2022;22:425. doi: 10.1186/s12877-022-03115-2.
  26. Kochar Ajar, et al. Temporal Trends in Post Myocardial Infarction Heart Failure and Outcomes Among Older Adults. J Cardiac Failure. 2022;28,4:531–39. doi: 10.1016/j.cardfail.2021.09.001.
  27. Chua S.K., Huang P.S., Chen J.J., et al. Use of the CHA2DS2-VASc score to predict subsequent myocardial infarction in atrial fibrillation. Hellenic J Cardiol. Published on-line August 25, 2023. doi: 10.1016/j.hjc.2023.08.010.
  28. Sarwar N., Gao P., Seshasai S.R.K. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England). 2010;375(9733):2215–22. doi: 10.1016/S0140-6736(10)60484-9.
  29. Haffner S.M., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34. doi: 10.1056/NEJM199807233390404.
  30. Anavekar Nagesh S., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95. doi: 10.1056/NEJMoa041365.
  31. Lip Gregory Y.H., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. doi: 10.1001/jama.285.22.2864.
  32. Charlson M.E., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–83. doi: 10.1016/0021-9681(87)90171-8.
  33. Gabarin M., et al. CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. Am J Cardiol. 2022;180:24–8. doi: 10.1016/j.amjcard.2022.06.052.
  34. Boyd Cynthia M., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. doi: 10.1001/jama.294.6.716.
  35. Holmes H.M., et al. Reconsidering medication appropriateness for patients late in life. Arch Int Med. 2006;166(6):605–9. doi: 10.1001/archinte.166.6.605.
  36. Piccini J.P., Hellkamp A.S., Washam J.B., et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133:352–60. doi: 10.1161/CIRCULATIONAHA.115.018544.
  37. Jaspers Focks J., Brouwer M.A., Wojdyla D.M., et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. doi: 10.1136/bmj.i2868.
  38. Proietti M., Raparelli V., Olshansky B., Lip G.Y. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105:412–20. doi: 10.1007/s00392-015-0936-y.
  39. Ryan C., et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936–47. doi: 10.1111/j.1365-2125.2009.03531.x.
  40. Garcia-Gollarte F., Baleriola-Julvez J., Ferrero-Lopez I., Cruz-Jentoft A. Inappropriate drug prescription at nursing home admission. J Am Med Dir Assoc. 2012;13:83.e9–83.e15. doi: 10.1016/j.jamda.2011.02.009.
  41. Hill-Taylor B., et al. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72. Doi: 10.1111/ jcpt.12059.
  42. Стабильная ишемическая болезнь сердца. Клинические рекомендации. Одобрено Научно-практическим cоветом Минздрава РФ. 2020. [Clinical recommendations “Stable coronary heart disease”. Year of approval: 2020. [Internet] [city 2023, Dec 01] (In Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/ 155_1.
  43. Рекомендации ЕОК/ЕОСХ по диагностике и лечению заболеваний периферических артерий 2017. Российский кардиологический журнал. 2018;(8):164–221. [2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Russ J Cardiol. 2018;(8):164–221 (In Russ.)]. doi: 10.15829/1560–4071–2018–8–164–221.
  44. Ramalho S.H.R., Shah A.M. Lung function and cardiovascular disease: A link. Trends Cardiovasc Med. 2021;31(2):93–8. doi: 10.1016/j.tcm.2019.12.009.
  45. Sin Don D., et al. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–59. doi: 10.1378/chest.127.6.1952.
  46. Клинические рекомендации «Хроническая боль у пациентов пожилого и старческого возраста». Год утверждения: 2020. [Internet] [cited 2023 Dec 01]. [Clinical recommendations “Chronic pain in elderly and senile patients”. Year of approval: 2020. [Internet] [city 2023, Dec 01] (In Russ.)]. ГКДЖ https://cr.minzdrav.gov.ru/schema/616_1.
  47. Ribeiro H., et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. Biomed Pharmacother. 2022;150:112958. doi: 10.1016/j.biopha.2022.112958.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (88KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies